🇨🇭 Swiss Precision & Compliance

Clinical trial software
for emerging and mid-sized biopharma

With oomnia, all core trial tools come together in one clinical research information system (CRIS) and help biopharma teams scale clinical trials with confidence.

21 CFR Part 11 ICH-GCP GDPR GxP-aligned

Industry Challenges

Industry challenges in emerging and mid-sized biopharma

Emerging and mid-sized biopharma companies operate in an environment where rapid scientific progress, expanding data requirements, and increasing regulatory expectations place significant strain on limited operational resources. Common challenges include:

  1. First investigational new drug application (IND) submission remains a critical milestone, requiring precise data management and regulatory alignment from day one

  2. Inconsistent data standards across vendors require manual alignment

  3. Difficulty maintaining compliance across disconnected workflows

  4. Managing CROs, sites, and partners without unified oversight

  5. Challenges scaling studies across countries and therapeutic areas without unified systems

  6. Limited end-to-end traceability and incomplete audit trails reduce inspection readiness

Our Solution

Wemedoo's clinical trial solution for emerging and mid-sized biopharma

One unified system for clinical operation

A unified CRIS enables emerging and mid-sized biopharma teams to oversee all clinical operations, from first IND submission through study expansion across phases and regions.

Real-time visibility across studies

Sponsors gain real-time insight into enrollment, site performance, subject data, and documentation.

Faster study start-up and standardized processes

Reusable templates, standardized processes, and automated startup workflows.

Built-in compliance support for modern biopharma

Integrated audit trails, controlled e-signatures, and validation-ready workflows ensure alignment with FDA, EMA, and global regulatory expectations.

The Platform

All clinical trial tools unified in one clinical trial platform

Why It Matters

Why unified clinical trial software matters

Many emerging biopharma teams rely on multiple standalone systems connected through integrations. While flexible, this approach introduces complexity and limits visibility across studies.

A unified clinical trial platform, built as a Clinical Research Information System (CRIS), connects all study functions within a single environment.

This enables consistent data flow, improved oversight across CROs and sites, and more efficient execution of growing clinical programs.

Modular eClinical Systems

Data spread across multiple tools

High manual reconciliation effort

Multiple audit logs across systems

Slower due to system fragmentation

Unified Clinical Trial Software (oomnia)

Data flows within one system in real time

Reduced reconciliation through shared data model

One unified audit trail

Faster study execution and scaling

SIDE BY SIDE

Modular eClinical system vs. Unified clinical trial software

Modular eClinical system vs. Unified clinical trial software
Area Modular eClinical system Unified clinical trial software (oomnia)
Data flow Data spread across multiple tools Data flows within one system in real time
Reconciliation High manual reconciliation effort Reduced reconciliation through shared data model
Visibility Limited, delayed insights Real-time study and operational visibility
Audit trails Multiple audit logs across systems One unified audit trail
Team workload Time spent aligning data More time for oversight and decision-making
Regulatory readiness Harder to maintain traceability Improved traceability and inspection readiness
Operational speed Slower due to system fragmentation Faster study execution and scaling

Regulatory Readiness

Compliance and regulatory readiness

The oomnia clinical trial software supports the strict regulatory expectations that biopharma organizations operate under, helping teams maintain consistent global compliance, manage documentation efficiently, and stay prepared for audits throughout the entire study lifecycle:

GxP-aligned processes

Supports GxP-aligned processes across all clinical operations

21 CFR Part 11

Fully compatible with 21 CFR Part 11 electronic records and signature requirements

ICH-GCP Standards

Workflows structured in accordance with ICH-GCP standards and oversight principles

GDPR

GDPR-aligned data protection and privacy control

Audit Trails

Automatic audit trails and complete data traceability

Validation Documentation

Clear validation documentation and ongoing support to keep the system compliant

Scale your clinical trials with greater control

See how a unified clinical trial platform can reduce operational complexity, improve visibility, and help your team move faster from study setup to execution.

Talk to our team

Frequently asked questions

What is clinical trial software for emerging and mid‑sized biopharma companies?

Clinical trial software for emerging and mid‑sized biopharma companies is a unified system that centralizes core study operations into one environment. oomnia provides all these capabilities in a single CRIS, helping smaller biopharma teams run studies more efficiently and prepare for future growth.

Why do emerging and mid‑sized biopharma organizations need unified clinical trial software?

Growing biopharma companies often operate with lean teams, multiple external vendors, and evolving study portfolios. A unified system reduces operational complexity, minimizes manual reconciliation, and provides real‑time oversight, enabling teams to move faster and stay in control, even with limited resources.

How does oomnia support distributed studies for emerging and mid‑sized biopharma?

oomnia provides real‑time visibility into enrollment, site performance, documentation, and subject data across all partners and study locations. This helps emerging and mid‑sized sponsors maintain consistency, reduce delays, and make timely decisions, even when relying on CROs and global sites.

Which clinical trial tools are included in oomnia’s unified software?

oomnia includes all essential eClinical modules:
  • EDC for clinical data capture
  • CTMS for study and site oversight
  • eTMF for document and compliance management
  • RTSM for randomization and supply control
  • eConsent for digital informed consent
  • ePRO/eCOA for patient‑ and clinician‑reported outcomes
  • eSource for direct site data capture
All modules operate natively within a single clinical research information system (CRIS).

How does unified clinical trial software reduce data reconciliation work?

Because all modules share one data model and operate in one environment, data moves seamlessly across study functions. This removes the need for manual comparisons, spreadsheet checks, and cross‑system reconciliation.

Does oomnia improve oversight for emerging biopharma sponsors?

Yes. Sponsors gain real-time, role-based visibility into enrollment progress, data entry, site activity, subject status, and document completeness. This real‑time visibility supports faster decision‑making, especially important for lean teams managing multiple vendors or CROs.

Is oomnia suitable for biopharma teams preparing to scale into more complex trials?

Yes. oomnia is built for organizations starting with smaller studies but expecting program expansion over time. The unified CRIS infrastructure supports increasing complexity, helping teams maintain consistency as they grow into larger, multi‑region or multi‑phase development programs.

How does oomnia support regulatory compliance for emerging and mid‑sized biopharma?

oomnia includes:
  • GxP‑aligned workflows
  • 21 CFR Part 11–ready e‑signatures and records
  • ICH‑GCP‑compliant processes
  • GDPR‑aligned data protection
  • Automated audit trails
  • Full traceability across study activities
  • Validation documentation and ongoing compliance support
These features help smaller biopharma organizations stay inspection‑ready without needing large compliance teams.

How does oomnia help maintain consistent global regulatory alignment?

Unified documentation, controlled versioning, standardized workflows, and built‑in audit trails ensure that processes align with FDA, EMA, and other global regulatory expectations, even when working with multiple study sites, CROs, or external partners.

Can oomnia help emerging biopharma scale studies across countries and therapeutic areas?

Yes. With all study modules inside one cloud‑native CRIS, organizations can scale operations more easily, onboard new sites quickly, and maintain consistent workflows across regions as their pipelines expand.

How does oomnia improve study startup for emerging and mid‑sized biopharma?

Standardized templates, automated workflows, and connected systems reduce administrative workload, allowing teams to configure studies, activate sites, and begin enrollment faster, critical for companies operating under tight timelines and budgets.

What makes oomnia different from modular eClinical setups commonly used by emerging biopharma?

Most emerging biopharma rely on a mix of disconnected tools from different vendors. oomnia replaces this fragmented setup with a single CRIS where all data, documents, and workflows operate together. This reduces manual work, eliminates data silos, and improves accuracy across the study.

Does oomnia support collaboration between sponsors and CRO partners?

Yes. oomnia is built for seamless collaboration between emerging biopharma sponsors, CROs, and study sites. All stakeholders work within the same environment, reducing duplicated work and improving operational transparency.

How does unified clinical trial software help biopharma teams stay inspection‑ready?

Automated audit trails, complete data traceability, centralized documentation, and compliant workflows ensure teams can demonstrate control and oversight at any point during a study, without scrambling to assemble information.

Ready to streamline your Biopharma studies?